Asia Pacific Oral Antibiotics 麻豆原创 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity

Publication ID:

GRM0820036

Publication Date:

August 26, 2020

Pages:

126

Publisher:

Grace 麻豆原创 Data

Countries:

Asia Pacific [1]

USD 3,200.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Asia Pacific oral antibiotics market will grow by 4.6% annually with a total addressable market cap of $103.3 billion over 2020-2030 owing to the rising infection complications associated with COVID-19 epidemic, development of innovative antibiotics, and growing healthcare expenditure.
Highlighted with 35 tables and 62 figures, this 126-page report 鈥淎sia Pacific Oral Antibiotics 麻豆原创 2020-2030 by Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Asia Pacific oral antibiotics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific oral antibiotics market in every aspect of the classification from perspectives of Drug Class, Action Mechanism, Drug Origin, Activity Spectrum, Application, Drug Type, and Country.

Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Cephalosporin
鈥� Cefuroxime Axetil
鈥� Cephalexin
鈥� Cefixime
鈥� Cefpodoxime
鈥� Other Cephalosporin
Penicillin
Macrolides
Tetracycline
Quinolones
Sulfonamides
Aminoglycosides
Other Drug Classes

Based on Action Mechanism, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Cell Wall Synthesis Inhibitors
鈥� Mycolic Acid Inhibitors
鈥� RNA Synthesis Inhibitors
鈥� DNA Synthesis Inhibitors
鈥� Protein Synthesis Inhibitors
鈥� Other Mechanisms

Based on Drug Origin, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Natural Antibiotics
鈥� Semi-synthetic Antibiotics
鈥� Synthetic Antibiotics

Based on Activity Spectrum, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Broad-spectrum Antibiotics
鈥� Narrow-spectrum Antibiotics

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Urinary Tract Infections (UTIS)
鈥� Upper Respiratory Tract Infections (URTI)
鈥� Lower Respiratory Tract Infections (LRTIs)
Dental Infections
鈥� Monotherapies
鈥� Combined Therapies
Respiratory Tract Infections (RTIS)
Other Applications

Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
鈥� Brand Antibiotics
鈥� Generic Antibiotics

Geographically, the following national/local markets are fully investigated:
鈥� Japan
鈥� China
鈥� South Korea
鈥� Australia
鈥� India
鈥� Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Drug Class, Drug Origin, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific oral antibiotics market are assayed quantitatively and qualitatively through GMD鈥檚 Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy鈥檚 Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Table Of Contents:

1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 14
1.2.6 麻豆原创 Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 麻豆原创 Overview and Dynamics 20
2.1 麻豆原创 Size and Forecast 20
2.1.1 Impact of COVID-19 on the 麻豆原创 21
2.2 Major Growth Drivers 23
2.3 麻豆原创 Restraints and Challenges 27
2.4 Emerging Opportunities and 麻豆原创 Trends 30
2.5 Porter鈥檚 Fiver Forces Analysis 34
3 Segmentation of Asia Pacific 麻豆原创 by Drug Class 38
3.1 麻豆原创 Overview by Drug Class 38
3.2 Cephalosporin 40
3.3 Penicillin 42
3.4 Macrolides 43
3.5 Tetracycline 44
3.6 Quinolones 45
3.7 Sulfonamides 46
3.8 Aminoglycosides 47
3.9 Other Drug Classes 48
4 Segmentation of Asia Pacific 麻豆原创 by Action Mechanism 49
4.1 麻豆原创 Overview by Action Mechanism 49
4.2 Cell Wall Synthesis Inhibitors 51
4.3 Mycolic Acid Inhibitors 52
4.4 RNA Synthesis Inhibitors 53
4.5 DNA Synthesis Inhibitors 54
4.6 Protein Synthesis Inhibitors 55
4.7 Other Mechanisms 56
5 Segmentation of Asia Pacific 麻豆原创 by Drug Origin 57
5.1 麻豆原创 Overview by Drug Origin 57
5.2 Natural Antibiotics 59
5.3 Semi-synthetic Antibiotics 60
5.4 Synthetic Antibiotics 61
6 Segmentation of Asia Pacific 麻豆原创 by Activity Spectrum 62
6.1 麻豆原创 Overview by Activity Spectrum 62
6.2 Broad-spectrum Antibiotics 64
6.3 Narrow-spectrum Antibiotics 65
7 Segmentation of Asia Pacific 麻豆原创 by Application 66
7.1 麻豆原创 Overview by Application 66
7.2 Urinary Tract Infections (UTIS) 68
7.3 Dental Infections 69
7.3.1 Monotherapies for Dental Infections 70
7.3.2 Combined Therapies for Dental Infections 71
7.4 Respiratory Tract Infections (RTIS) 72
7.4.1 Upper Respiratory Tract Infections (URTI) 73
7.4.2 Lower Respiratory Tract Infections (LRTIs) 74
7.5 Other Applications 75
8 Segmentation of Asia Pacific 麻豆原创 by Drug Type 76
8.1 麻豆原创 Overview by Drug Type 76
8.2 Brand Antibiotics 78
8.3 Generic Antibiotics 79
9 Asia-Pacific 麻豆原创 2019-2030 by Country 80
9.1 Overview of Asia-Pacific 麻豆原创 80
9.2 Japan 83
9.3 China 86
9.4 Australia 88
9.5 India 90
9.6 South Korea 92
9.7 Rest of APAC Region 94
10 Competitive Landscape 96
10.1 Overview of Key Vendors 96
10.2 New Product Launch, Partnership, Investment, and M&A 99
10.3 Company Profiles 100
Abbott Laboratories 100
Astellas Pharma 102
AstraZeneca Plc 103
Bayer AG 104
Bristol Myers Squibb Company 105
Cipla Inc. 106
Dr. Reddy鈥檚 Laboratories Ltd. 107
Eli Lilly and Company 108
F. Hoffmann-La Roche Ltd. 109
Gilead Sciences, Inc. 110
GlaxoSmithKline plc. 111
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals) 112
Mayne Pharma Group Ltd. 113
MELINTA THERAPEUTICS, INC. 114
Merck KGaA 115
Novartis AG 116
Pfizer Inc. 117
Sanofi 118
Sun Pharmaceutical Industries Ltd. 119
11 Investing in Asia Pacific 麻豆原创: Risk Assessment and Management 120
11.1 Risk Evaluation of Asia Pacific 麻豆原创 120
11.2 Critical Success Factors (CSFs) 123
Related Reports and Products 126

Companies Mentioned:

Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
Astellas Pharma
AstraZeneca Plc
Bayer AG
Bristol Myers Squibb Company
Cipla Inc.
Dr. Reddy鈥檚 Laboratories Ltd.
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Gilead Sciences, Inc.
GlaxoSmithKline plc.
Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
Mayne Pharma Group Ltd.
MELINTA THERAPEUTICS, INC.
Merck KGaA
Novartis AG
Pfizer Inc.
Sanofi
Sun Pharmaceutical Industries Ltd.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.